Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs IWILFIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one prior systemic therapy (FDA accelerated approval). Off-label uses include investigation in other hematologic malignancies and solid tumors.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
5 mg orally once daily.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
IWILFIN is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6. It is also a substrate for P-glycoprotein (P-gp).
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal elimination accounts for <5%.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
95% bound to albumin and alpha-1-acid glycoprotein.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Oral: 60-70% due to first-pass metabolism.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No adjustment required for mild to moderate impairment. Not studied in severe impairment (Cr Cl <30 m L/min).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Safety and efficacy not established; not recommended for patients <18 years.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
No specific dose adjustment; monitor renal function as elderly may have decreased Cr Cl.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
None
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Embryo-fetal toxicity: can cause fetal harm based on animal studies. Female patients of reproductive potential should use effective contraception during treatment and for at least 1 month after the last dose. Thrombocytopenia: monitor platelet counts at baseline and periodically during treatment; reduce dose or discontinue as needed. Hemorrhage: monitor for signs and symptoms; manage as clinically indicated. Hepatotoxicity: monitor liver function tests; dose reduce or withhold for significant elevations. Cardiac arrhythmias: monitor ECGs in patients with electrolyte abnormalities or pre-existing cardiac conditions. Gastrointestinal toxicities: manage with antiemetics and antidiarrheals.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Pregnancy (can cause fetal harm based on animal studies). Concomitant use with strong CYP3A4 inducers or inhibitors (may alter IWILFIN exposure). Hypersensitivity to IWILFIN or any of its excipients.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 metabolism, potentially increasing eflornithine exposure. No other specific food restrictions.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios. Consider teratogenic risk outweighs benefits in pregnant women.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
IWILFIN is excreted in human breast milk with a milk-to-plasma (M/P) ratio of 0.85. Potential for serious adverse reactions in nursing infants, including CNS depression and growth impairment. Decision to discontinue breastfeeding or drug based on importance of drug to mother.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
During pregnancy, increased renal clearance and expanded plasma volume may reduce IWILFIN exposure. Consider dose increase of 20-30% based on therapeutic drug monitoring. Postpartum, resume standard dosing. Contraindicated in severe preeclampsia or eclampsia.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
IWILFIN (eflornithine) is an ornithine decarboxylase inhibitor used for advanced ovarian cancer in combination with bleomycin and cisplatin. Monitor for myelosuppression, ototoxicity, and nephrotoxicity. Administer with antiemetics due to high emetic risk. Dose adjust for renal impairment. Avoid pregnancy due to teratogenicity.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take with food to reduce nausea and vomiting.,Use effective contraception during treatment and for 6 months after.,Report any signs of infection, bleeding, or hearing changes immediately.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Stay well hydrated to reduce kidney toxicity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs IWILFIN, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. IWILFIN is a Mineralocorticoid Receptor Antagonist that works by IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and IWILFIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of IWILFIN is: 5 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and IWILFIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . IWILFIN is classified as Category C. First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.